Safety and survival analysis of haplo-identical hematopoietic stem cell transplantation in patients with severe aplastic anemia who had previous failure to antithymoglobulin treatment
10.3760/cma.j.cn112138-20221003-00727
- VernacularTitle:单倍体造血干细胞移植治疗抗胸腺球蛋白治疗失败重型再生障碍性贫血患者的安全性和生存分析
- Author:
Yu YU
1
;
Tingting HAN
;
Yuanyuan ZHANG
;
Yifei CHENG
;
Jingzhi WANG
;
Xiaodong MO
;
Fengrong WANG
;
Chenhua YAN
;
Yuhong CHEN
;
Wei HAN
;
Yuqian SUN
;
Haixia FU
;
Zhengli XU
;
Yu WANG
;
Feifei TANG
;
Kaiyan LIU
;
Xiaohui ZHANG
;
Xiaojun HUANG
;
Lanping XU
Author Information
1. 北京大学人民医院 北京大学血液病研究所 国家血液系统疾病临床医学研究中心，北京 100044
- Keywords:
Anemia, aplastic;
Hematopoietic stem cell transplantation;
Antithymoglobulin;
Haplo-identical allogeneic hematopoietic stem cell transplantation
- From:
Chinese Journal of Internal Medicine
2023;62(10):1209-1214
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the safety and efficacy of haplo-identical hematopoietic stem cell transplantation (haplo-HSCT) conditioning with the same dosage form of antithymoglobulin (ATG) in patients with severe aplastic anemia (SAA) failure to ATG.Methods:This was a retrospective cohort study. A total of 65 patients with SAA who failed ATG treatment and received haplo-HSCT conditioning with the same dosage of ATG at the Institute of Hematology, Peking University People′s Hospital between July 2008 and October 2020 were included as the ATG treatment failure group. An additional 65 SAA patients who applied ATG for the first time during haplo-HSCT were randomly selected by stratified sampling as the first-line haplo-HSCT group. Baseline clinical data and follow-up data of the two groups were collected. Conditioning-related toxicity within 10 days after ATG application and long-term prognosis were analyzed. The Kaplan-Meier was used to calculate the overall survival rate, and the Log-rank test was applied to compare the rates of the two groups.Results:In the ATG treatment failure group, there were 36 males and 29 females, and the age at the time of transplantation [ M ( Q1, Q3)] was 16 (8, 25) years. In the first-line haplo-HSCT group, there were 35 males and 30 females, with a median age of 17 (7, 26) years. Within 10 days of ATG application, the incidence of noninfectious fever, noninfectious diarrhea, and liver injury in the ATG treatment failure group was 78% (51 cases), 45% (29 cases), and 28% (18 cases), respectively, and in the first-line haplo-HSCT group was 74% (48 cases), 54% (35 cases), and 25% (16 cases), respectively; the difference between the two groups was not statistically significant for any of these three parameters (all P>0.05). For graft-versus-host disease (GVHD), there was no significant difference between the ATG treatment failure group and the first-line haplo-HSCT group in the development of 100 day Ⅱ to Ⅳ acute GVHD (29.51%±0.35% vs. 25.42%±0.33%), Ⅲ to Ⅳ acute GVHD (6.56%±0.10% vs. 6.78%±0.11%), and 3-year chronic GVHD (26.73%±0.36% vs. 21.15%±0.30%) (all P>0.05). Three-year overall survival (79.6%±5.1% vs. 84.6%±4.5%) and 3-year failure-free survival (79.6%±5.1% vs. 81.5%±4.8%) were also comparable between these two groups (both P>0.05). Conclusions:Compared with no exposure to ATG before HSCT, similar early adverse effects and comparable survival outcomes were achieved in patients with SAA who failed previous ATG treatment and received haplo-HSCT conditioning with the same dosage form of ATG. This might indicate that previous failure of ATG treatment does not significantly impact the efficacy and safety of salvaging haplo-HSCT in patients with SAA.
